Dysfunctional fat cells, lipotoxicity and type 2 diabetes - PubMed (original) (raw)

Review

Dysfunctional fat cells, lipotoxicity and type 2 diabetes

R A DeFronzo. Int J Clin Pract Suppl. 2004 Oct.

Abstract

Type 2 diabetes is characterized by insulin resistance and impaired insulin secretion. Considerable evidence implicates altered fat topography and defects in adipocyte metabolism in the pathogenesis of type 2 diabetes. In individuals who develop type 2 diabetes, fat cells tend to be enlarged. Enlarged fat cells are resistant to the antilipolytic effects of insulin, leading to day-long elevated plasma free fatty acid (FFA) levels. Chronically increased plasma FFA stimulates gluconeogenesis, induces hepatic and muscle insulin resistance, and impairs insulin secretion in genetically predisposed individuals. These FFA-induced disturbances are referred to as lipotoxicity. Enlarged fat cells also have diminished capacity to store fat. When adipocyte storage capacity is exceeded, lipid 'overflows' into muscle and liver, and possibly the beta-cells of the pancreas, exacerbating insulin resistance and further impairing insulin secretion. In addition, dysfunctional fat cells produce excessive amounts of insulin resistance-inducing, inflammatory and atherosclerosis-provoking cytokines, and fail to secrete normal amounts of insulin-sensitizing cytokines. As more evidence emerges, there is a stronger case for targeting adipose tissue in the treatment of type 2 diabetes. Peroxisome-proliferator activated receptor gamma (PPARgamma) agonists, for example the thiazolidinediones, redistribute fat within the body (decrease visceral and hepatic fat; increase subcutaneous fat) and have been shown to enhance adipocyte insulin sensitivity, inhibit lipolysis, reduce plasma FFA and favourably influence the production of adipocytokines. This article examines in detail the role of adipose tissue in the pathogenesis of type 2 diabetes and highlights the potential of PPAR agonists to improve the management of patients with the condition.

PubMed Disclaimer

Similar articles

• Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas.
  Souza-Tavares H, Miranda CS, Vasques-Monteiro IML, Sandoval C, Santana-Oliveira DA, Silva-Veiga FM, Fernandes-da-Silva A, Souza-Mello V. Souza-Tavares H, et al. World J Gastroenterol. 2023 Jul 14;29(26):4136-4155. doi: 10.3748/wjg.v29.i26.4136. World J Gastroenterol. 2023. PMID: 37475842 Free PMC article. Review.
• Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones.
  Smith SA. Smith SA. Biochimie. 2003 Dec;85(12):1219-30. doi: 10.1016/j.biochi.2003.10.010. Biochimie. 2003. PMID: 14739074 Review.
• Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage.
  Raz I, Eldor R, Cernea S, Shafrir E. Raz I, et al. Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):3-14. doi: 10.1002/dmrr.493. Diabetes Metab Res Rev. 2005. PMID: 15386813 Review.
• Rosiglitazone ameliorates skeletal muscle insulin resistance by decreasing free fatty acids release from adipocytes.
  Gong L, Jin H, Li Y, Quan Y, Yang J, Tang Q, Zou Z. Gong L, et al. Biochem Biophys Res Commun. 2020 Dec 17;533(4):1122-1128. doi: 10.1016/j.bbrc.2020.09.144. Epub 2020 Oct 6. Biochem Biophys Res Commun. 2020. PMID: 33036752
• [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
  Dubois M, Vantyghem MC, Schoonjans K, Pattou F. Dubois M, et al. Ann Endocrinol (Paris). 2002 Dec;63(6 Pt 1):511-23. Ann Endocrinol (Paris). 2002. PMID: 12527853 Review. French.

Cited by

• The mitochondrial pyruvate carrier regulates adipose glucose partitioning in female mice.
  Shannon CE, Bakewell T, Fourcaudot MJ, Ayala I, Smelter AA, Hinostroza EA, Romero G, Asmis M, Freitas Lima LC, Wallace M, Norton L. Shannon CE, et al. Mol Metab. 2024 Oct;88:102005. doi: 10.1016/j.molmet.2024.102005. Epub 2024 Aug 11. Mol Metab. 2024. PMID: 39137831 Free PMC article.
• Sex-dependent adipose glucose partitioning by the mitochondrial pyruvate carrier.
  Shannon CE, Bakewell T, Fourcaudot MJ, Ayala I, Romero G, Asmis M, Lima LCF, Wallace M, Norton L. Shannon CE, et al. bioRxiv [Preprint]. 2024 May 14:2024.05.11.593540. doi: 10.1101/2024.05.11.593540. bioRxiv. 2024. PMID: 38798427 Free PMC article. Updated. Preprint.
• Untargeted metabolomics based on ultra-high performance liquid chromatography-mass spectrometry/MS reveals the lipid-lowering mechanism of taurine in hyperlipidemia mice.
  Guo X, Ou T, Yang X, Song Q, Zhu L, Mi S, Zhang J, Zhang Y, Chen W, Guo J. Guo X, et al. Front Nutr. 2024 Apr 19;11:1367589. doi: 10.3389/fnut.2024.1367589. eCollection 2024. Front Nutr. 2024. PMID: 38706565 Free PMC article.
• Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas.
  Souza-Tavares H, Miranda CS, Vasques-Monteiro IML, Sandoval C, Santana-Oliveira DA, Silva-Veiga FM, Fernandes-da-Silva A, Souza-Mello V. Souza-Tavares H, et al. World J Gastroenterol. 2023 Jul 14;29(26):4136-4155. doi: 10.3748/wjg.v29.i26.4136. World J Gastroenterol. 2023. PMID: 37475842 Free PMC article. Review.
• Obesity-related parameters in carriers of some BDNF genetic variants may depend on daily dietary macronutrients intake.
  Miksza U, Adamska-Patruno E, Bauer W, Fiedorczuk J, Czajkowski P, Moroz M, Drygalski K, Ustymowicz A, Tomkiewicz E, Gorska M, Kretowski A. Miksza U, et al. Sci Rep. 2023 Apr 21;13(1):6585. doi: 10.1038/s41598-023-33842-4. Sci Rep. 2023. PMID: 37085692 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program